1. 1 Presentation 2006 Preliminary Results April 2007 The Quantitative MindReading Agency

2. 2 Disclaimer The information in this document and the related presentation do not constitute or form any part of, and should not be construed as, an offer or invitation to sell, or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any share or other securities in Brainjuicer Group Limited ("Brainjuicer") in any jurisdiction, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this document and the presentation or their completeness. No representation or warranty, expressed or implied, is given on behalf of Brainjuicer or any of its respective directors, employees, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained herein or made in the presentation and, save in the case of fraud, no responsibility or liability is accepted (and all such liability is hereby excluded) for any such information or opinions. Readers of this document and recipients of the presentation are reminded that any decision to acquire shares in Brainjuicer should be made only on the basis of information contained in the final admission document to be issued by Brainjuicer which may be different from the information contained in this document. The information in this document may not be reproduced or further distributed to any other person or published, in whole or in part, for any purpose. Neither this document (or any copy of it) nor the information in the presentation may be sent or taken into the United States, Canada, Australia or Japan, nor may it be distributed to any US person (within the meaning of regulation S under the US Securities Act of 1933, as amended). Furthermore, this document and presentation are strictly only for persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI 2001/1335), as amended, (the "FPO") or persons falling within paragraph 49 of the FPO (high net worth companies, unincorporated associations etc.) or to persons to whom it may otherwise be lawful for these materials to be communicated ("Permitted Recipients"). Any persons who are not Permitted Recipients should not stay for the remainder of this presentation and, in any event, must not act or rely upon the information contained in this presentation and document. By staying for the remainder of this presentation and/or receiving this document, each participant is deemed to confirm that they are a Permitted Recipient.

3. 3  A leading international online market research agency  Innovative, bespoke software produces insightful research  Multinational client base; 10 of world’s top 50 companies  Over 80 clients, research in over 50 countries, over 30 languages  Online research is a high growth market  Focused and scaleable online business model About BrainJuicer®

4. 4 ESOMAR 2005 Industry Report + Inside Research US & European Online MR Spending Index Growth of Market Research Compound growth = 41%Compound growth = 375%

5. 5 BrainJuicer Offering the Best of Both… QualitativeQuantitative  Consumer habits/attitudes  Consumer Segmentation  Brand/Market Mapping  Consumer Deep-Dive  Volume Predictions  Concept testing  Insight testing  Pack testing  Ad testing  Tracking  Spontaneous thoughts  Creative projections  Free associations  Idea generation  Reasons why  Best/worst Robust data & Rich Insights

6. 6 Tracking Launch Screening Evaluation Prediction Exploration BrainJuicer Products Multi-nationals Large Domestics

7. 7 Financials  Revenue increased by 57% to £4.6m (2005: £2.9m)  Operating profit (before listing costs) increased to £477k (2005: £2k)  Profit after tax (before listing costs) increased to £291k (2005: loss £38k)

8. 8  All business units performed well:  172% revenue growth in the Netherlands in 2 nd year of operation  Continued strong performance in UK  Established our business in the US  Developed key clients:  Awarded global mandate from one of the top 50 companies in the world  85% of 2006 revenue from repeat business  Strengthened management team:  Senior researcher joined from Research International to run UK  And another from Millward Brown to run the US  Rolled out 2 important new products:  Predictive Markets  Quali-Taxi Operations

9. 9 Consolidated Income Statement 2006 Before Listing expenses 2006 Listing expenses 2006 Total 2005 £’000 Revenue4,608- 2,936 Cost of sales(1,189) - (650) Gross profit3,419 - 2,286 Administrative expenses(2,942) (354) (3,296) (2,284) Operating profit477 (354) 123 2 Investment income3 - 3 4 Finance costs(32) - (44) Profit / (loss) before taxation448 (354) 94 (38) Income tax expense(157) - - Profit / (loss) for the financial year291 (354) (63)(38) Attributable to equity holders of the Company(63)(38) Earnings per share attributable to the equity holders of the Company Basic loss per share(0.9p)(0.6p) Diluted loss per share(0.9p)(0.6p)

10. 10 Balance Sheet 20062005 £’000 ASSETS Non-current assets Property, plant and equipment78 - Deferred tax asset 213- 291 - Current assets Inventories45 13 Trade and other receivables1,612 788 Cash and cash equivalents 1,23364 2,890865 Total assets 3,181865 EQUITY Capital and reserves attributable to equity holders of the Company Share capital 126111 Share premium account 1,390- Reserves 727472 Retained earnings (277)(214) Total equity 1,966369 LIABILITIES Current liabilities Trade and other payables944 408 Current income tax liabilities163 - Financial liabilities108 - 1,215 408 Non-current liabilities Financial liabilities -88 Total liabilities 1,215496 Total equity and liabilities 3,181865

11. 11 Management Team 12 years marketing and research experience Head of Market Research at Bestfood Unilever Marketing MD NL Evert Bos MD US Ari Popper 9 years marketing and research experience VP Millward Brown 20 years market research experience General Manager at SGA Research International MD UK Jim Rimmer CEO John Kearon 20 years experience Unilever Research/Mktg Publicis Planning Director Founder Brand Genetics E&Y Emerging Entrepreneur of Year 20 years financial management experience CFO of IOBox - sold to Telefonica Assistant Treasurer of Fosters Brewing Group CFO James Geddes

12. 12 Strategy for Growth 20% New Clients Existing Clients 80% New Products Geographic expansion Continued technology improvements

13. 13 BrainJuicer Differentiators Innovative suite of products Team of talented research professionals and software engineers Bespoke software delivering greater diagnostic insights Offices in 3 countries 375% online market research growth 2000-2005 Reputation as innovation leader Multinational client base, 10 of top 50 global co’s

14. 14 The Quantitative MindReading Agency Appendix Background

15. 15 Market Research Landscape N.B. ‘BrainJuicer’ logo indicates where the group operates rather than market share

16. 16 2000 Offline Online Advantages More representative Scaleable Faster fieldwork Greater honesty No interviewer effect Global reach Rich media capability Engaging interactivity Offline Advantages Representative than online Greater tactile capabilities More depth & breadth possibilities Market Research Evolution US online MR 10% EU online MR <1% 20062010 BrainJuicer Online Estimate US online MR 33% EU online MR 3% US online MR >50% EU online MR >30%

17. 17 Tracking Launch Screening Evaluation Prediction Exploration Cif Power Cream Case Study Predictive Market x15 Concept Optimizer x 2 6 wks14 wks19 wks16 wks 2 wks6 wks8 wks 30 mths to launch 14 mths to launch  Predictive Markets; unique screening methodology “In less than a year and a half, we’ve launched a great new product and broken every internal speed to market record we’re aware of. It’s quite an achievement. Thanks” Nicky Boud Unilever Research Director  Successfully launched across Europe 2005  MindReader diagnostics precluded need for focus groups  Concept Optimizer; Diagnostics aided development